Prophylaxis Recommendations for Adults and Children with AIDS (CD < 200 cells/µL)

Pneumocystis pneumonia (PCP) Primary Prophylaxis

• All adults with AIDS and CD4 < 200 cells/µL should receive trimethoprim‑sulfamethoxazole (TMP‑SMX) double‑strength (800/160 mg) once daily to prevent PCP, toxoplasmosis (if seropositive), and reduce bacterial respiratory infections. CDC recommendation. 1, 2
• Initiate TMP‑SMX double‑strength once daily as soon as CD4 falls below 200 cells/µL; this is the cornerstone regimen for PCP prophylaxis. CDC recommendation. 3, 1, 2

Toxoplasmosis Primary Prophylaxis

• In Toxoplasma‑IgG‑positive patients with CD4 < 100 cells/µL, the same daily TMP‑SMX double‑strength tablet provides adequate prophylaxis; no additional agent is required. CDC recommendation. 1, 4, 2
• Test Toxoplasma IgG serology immediately if not previously documented; if positive and CD4 < 100 cells/µL, continue TMP‑SMX alone. CDC recommendation. 1, 4
• Retest seronegative patients for Toxoplasma IgG when CD4 falls below 100 cells/µL to detect seroconversion. CDC recommendation. 1, 4

Mycobacterium avium complex (MAC) Primary Prophylaxis

• Azithromycin 1200 mg weekly is the preferred MAC prophylaxis for patients with CD4 < 50 cells/µL. Annals of Internal Medicine evidence. 5
• Clarithromycin 500 mg twice daily is equally effective but has more drug‑interaction concerns with protease inhibitors. Annals of Internal Medicine evidence. 5
• Rifabutin 300 mg daily is a second‑line option; it requires dose adjustments with most antiretrovirals and active‑TB exclusion before initiation. Annals of Internal Medicine evidence. 5

Management of TMP‑SMX Intolerance

• Approximately 70 % of patients who experience non‑life‑threatening TMP‑SMX reactions can tolerate drug re‑initiation after the reaction resolves (desensitization may be attempted). CDC recommendation. 2

PCP‑Only Alternative Regimens

• Dapsone 100 mg daily provides PCP prophylaxis only (no toxoplasmosis protection). CDC recommendation. 3, 2
• Atovaquone 1500 mg daily provides PCP prophylaxis only; efficacy comparable to dapsone but substantially more expensive. CDC recommendation. 2
• Aerosolized pentamidine 300 mg monthly via Respirgard II nebulizer is the least preferred option; it offers PCP protection only and no systemic or toxoplasmosis coverage. CDC recommendation. 2

Combined PCP & Toxoplasmosis Alternatives (TMP‑SMX‑intolerant, IgG‑positive)

• Dapsone 50 mg daily + pyrimethamine 50 mg weekly + leucovorin 25 mg weekly can be used when TMP‑SMX cannot be tolerated. CDC recommendation. 3, 1, 2

Discontinuation and Restart of Prophylaxis After Immune Reconstitution

• Prophylaxis may be safely stopped after sustained CD4 recovery on ART for ≥ 3 months with virologic suppression:
  
  • PCP & toxoplasmosis: CD4 > 200 cells/µL
  • MAC: CD4 > 100 cells/µL
    CDC recommendation. 1, 2

• Re‑initiate PCP and toxoplasmosis prophylaxis if CD4 falls below 200 cells/µL. CDC recommendation. 1, 2
• Re‑initiate MAC prophylaxis if CD4 falls below 50–100 cells/µL. Annals of Internal Medicine evidence. 5
• Never discontinue prophylaxis based on a single CD4 measurement; sustained elevation for the full 3‑month period is mandatory. CDC recommendation. 1, 2

Critical Pitfalls to Avoid

• Never use aerosolized pentamidine as sole prophylaxis when CD4 < 100 cells/µL because it does not protect against toxoplasmosis. CDC recommendation. 1, 4
• Never combine clarithromycin with rifabutin for MAC prophylaxis; this increases adverse effects without improving efficacy. Annals of Internal Medicine evidence. 5
• Never discontinue prophylaxis prematurely; CD4 must remain above the specified threshold for at least three consecutive months on ART. CDC recommendation. 1, 2

Drug‑Interaction Management for MAC Prophylaxis

• Azithromycin is preferred over clarithromycin for MAC prophylaxis due to fewer interactions with protease inhibitors. Annals of Internal Medicine evidence. 5
• Rifabutin requires dose adjustments when co‑administered with most protease inhibitors and NNRTIs. Annals of Internal Medicine evidence. 5
• Active tuberculosis must be excluded before starting rifabutin to avoid inducing rifampin resistance. Annals of Internal Medicine evidence. 5

Special Populations

Pregnant Women

• Administer TMP‑SMX for PCP and toxoplasmosis prophylaxis using the same indications as non‑pregnant adults. CDC recommendation. 3
• During the first trimester, prophylaxis may be withheld due to theoretical teratogenicity; aerosolized pentamidine can be considered because it lacks systemic absorption. CDC recommendation. 3

Children

• HIV‑infected infants born to HIV‑positive mothers should receive TMP‑SMX beginning at 4–6 weeks of age, continuing through the first year of life. CDC recommendation. 3, 1
• Subsequent prophylaxis decisions for children should be based on age‑specific CD4 thresholds. CDC recommendation. 3, 1

Prophylaxis Recommendations for HIV Patients

Primary Prophylaxis Recommendations

• The Centers for Disease Control and Prevention recommends initiating PCP prophylaxis in HIV-infected patients with CD4 count <200 cells/µL, including those with a CD4 count of 105 cells/µL 6, 7
• The American College of Physicians suggests that other indications for prophylaxis regardless of CD4 count include a history of oropharyngeal candidiasis 6, 8
• The Infectious Diseases Society of America recommends prophylaxis for patients with unexplained fever (>100°F/37.7°C) for ≥2 weeks 6, 9
• The Centers for Disease Control and Prevention advises that a history of a previous PCP episode is an indication for secondary prophylaxis 6, 10

First-Line Regimen

• The Centers for Disease Control and Prevention recommends TMP-SMX one double-strength tablet (800 mg sulfamethoxazole/160 mg trimethoprim) daily as the first-line prophylaxis for PCP prevention 6, 7

Benefits of TMP-SMX

• The American College of Physicians notes that TMP-SMX provides cross-protection against toxoplasmosis 6, 8
• The Infectious Diseases Society of America states that TMP-SMX offers protection against many common respiratory bacterial infections 6, 7

Alternative Prophylactic Regimens

• The Centers for Disease Control and Prevention suggests considering dapsone 100 mg orally once daily as an alternative regimen if TMP-SMX is not tolerated 6, 7
• The American College of Physicians recommends dapsone 50 mg daily plus pyrimethamine 50 mg weekly plus leucovorin 25 mg weekly as an alternative regimen that provides additional protection against toxoplasmosis 6, 7

Managing TMP-SMX Adverse Reactions

• The Infectious Diseases Society of America advises attempting to continue TMP-SMX if clinically feasible for non-life-threatening reactions 6, 7
• The American College of Physicians suggests considering gradual reintroduction with dose escalation (desensitization) or reduced dosage or frequency for patients who discontinued TMP-SMX due to adverse reactions 7

Duration of Prophylaxis

• The Centers for Disease Control and Prevention recommends continuing prophylaxis indefinitely unless immune reconstitution occurs with antiretroviral therapy 11, 10
• The American College of Physicians suggests considering discontinuing primary prophylaxis if CD4 count increases to >200 cells/µL for at least 3 months in response to antiretroviral therapy 11, 10

Special Considerations

• The Infectious Diseases Society of America recommends checking CD4 counts at least every 3 months 12
• The American College of Physicians advises monitoring for adverse reactions to TMP-SMX, including rash, fever, cytopenias, and transaminase elevations 12
• The Centers for Disease Control and Prevention suggests testing for glucose-6-phosphate dehydrogenase deficiency before initiating dapsone therapy 13
• The American College of Obstetricians and Gynecologists recommends TMP-SMX for pregnant women with the same indications as non-pregnant adults 10